These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

186 related items for PubMed ID: 3925558

  • 1. Cellular and clinical pharmacology of low-dose ara-C.
    Kufe DW, Griffin JD, Spriggs DR.
    Semin Oncol; 1985 Jun; 12(2 Suppl 3):200-7. PubMed ID: 3925558
    [Abstract] [Full Text] [Related]

  • 2. Effects of 1-beta-D-arabinofuranosylcytosine incorporation on eukaryotic DNA template function.
    Kufe DW, Munroe D, Herrick D, Egan E, Spriggs D.
    Mol Pharmacol; 1984 Jul; 26(1):128-34. PubMed ID: 6431261
    [Abstract] [Full Text] [Related]

  • 3. Low-dose cytosine arabinoside (Ara-C) therapy in the myelodysplastic syndromes and acute leukemia.
    Winter JN, Variakojis D, Gaynor ER, Larson RA, Miller KB.
    Cancer; 1985 Aug 01; 56(3):443-9. PubMed ID: 3859362
    [Abstract] [Full Text] [Related]

  • 4. Effect of antimetabolites and thymidine blockage on the induction of differentiation of HL-60 cells by retinoic acid or 1 alpha,25-dihydroxyvitamin D3.
    Ishikura H, Okazaki T, Mochizuki T, Izumi Y, Tashima M, Sawada H, Uchino H.
    Exp Hematol; 1985 Nov 01; 13(10):981-8. PubMed ID: 3932088
    [Abstract] [Full Text] [Related]

  • 5. Effect of ara-A on differentiation and proliferation of HL-60 cells.
    Munroe D, Sugiura M, Griffin J, Kufe D.
    Leuk Res; 1984 Nov 01; 8(3):355-61. PubMed ID: 6589455
    [Abstract] [Full Text] [Related]

  • 6. Induction of terminal differentiation in human K562 erythroleukemia cells by arabinofuranosylcytosine.
    Luisi-DeLuca C, Mitchell T, Spriggs D, Kufe DW.
    J Clin Invest; 1984 Sep 01; 74(3):821-7. PubMed ID: 6590568
    [Abstract] [Full Text] [Related]

  • 7. Isolation and characterization of a deoxycytidine kinase-deficient human promyelocytic leukemic cell line highly resistant to 1-beta-D- arabinofuranosylcytosine.
    Bhalla K, Nayak R, Grant S.
    Cancer Res; 1984 Nov 01; 44(11):5029-37. PubMed ID: 6091869
    [Abstract] [Full Text] [Related]

  • 8. Potentiation of ara-C induced cytotoxicity by hydroxyurea in LoVo colon carcinoma cells.
    Robichaud NJ, Fram RJ.
    Biochem Pharmacol; 1987 May 15; 36(10):1673-7. PubMed ID: 3109427
    [Abstract] [Full Text] [Related]

  • 9. Studies on the mechanism of action of cytosine arabinoside.
    Kufe DW, Major PP.
    Med Pediatr Oncol; 1982 May 15; 10 Suppl 1():49-67. PubMed ID: 6761569
    [Abstract] [Full Text] [Related]

  • 10. In vitro exposure of leukemic cells to low concentration Arabinosyl Cytosine: no evidence of differentiation inducing activity.
    Motta MR, Baccarani M, Rizzi S, Fanin R, Fasola G, Poluzzi C, Tura S.
    Blut; 1987 May 15; 54(5):299-306. PubMed ID: 3567369
    [Abstract] [Full Text] [Related]

  • 11. Induction of differentiation of human myeloid leukemia cells by inhibitors of DNA synthesis.
    Griffin J, Munroe D, Major P, Kufe D.
    Exp Hematol; 1982 Oct 15; 10(9):774-81. PubMed ID: 6816625
    [Abstract] [Full Text] [Related]

  • 12. In vitro evidence for dose-dependent cytotoxicity as the predominant effect of low dose Ara-C on human leukemic and normal marrow cells.
    Chan CS, Schechter GP.
    Cancer Chemother Pharmacol; 1989 Oct 15; 23(2):87-94. PubMed ID: 2910516
    [Abstract] [Full Text] [Related]

  • 13. DNA strand breaks caused by inhibitors of DNA synthesis: 1-beta-D-arabinofuranosylcytosine and aphidicolin.
    Fram RJ, Kufe DW.
    Cancer Res; 1982 Oct 15; 42(10):4050-3. PubMed ID: 6809309
    [Abstract] [Full Text] [Related]

  • 14. Deoxycytidine preferentially protects normal versus leukemic myeloid progenitor cells from cytosine arabinoside-mediated cytotoxicity.
    Bhalla K, MacLaughlin W, Cole J, Arlin Z, Baker M, Graham G, Grant S.
    Blood; 1987 Aug 15; 70(2):568-71. PubMed ID: 3607288
    [Abstract] [Full Text] [Related]

  • 15. Clinical pharmacology of low-dose cytosine arabinoside.
    Spriggs D, Griffin J, Wisch J, Kufe D.
    Blood; 1985 May 15; 65(5):1087-9. PubMed ID: 3995167
    [Abstract] [Full Text] [Related]

  • 16. [High-dose cytarabine treatment in acute leukemias and leukemic meningiosis: clinical aspects and pharmacokinetics].
    Nowrousian MR, Seeber S, Miller AA, Anders C, Ohl S, Schmidt CG.
    Onkologie; 1985 Feb 15; 8(1):26-32. PubMed ID: 3885117
    [Abstract] [Full Text] [Related]

  • 17. A study on the induction of differentiation of human leukemic cells by harringtonine combined with cytarabine.
    Huang CL, Deng ML, Guo RJ, Wu MT, Liu FZ, Liang YM, Qiao QD.
    Leukemia; 1988 Aug 15; 2(8):518-22. PubMed ID: 3412024
    [Abstract] [Full Text] [Related]

  • 18. Influence of small doses cytosine arabinoside (Ara-C) on leukemic cells in vitro and in vivo. Results in patients with leukemia and myelodysplastic syndrome.
    Kuliczkowski K, Kotlerek-Haus S, Frydecka I, Sedek K, Nowicka J.
    Folia Haematol Int Mag Klin Morphol Blutforsch; 1986 Aug 15; 113(6):738-48. PubMed ID: 2436986
    [Abstract] [Full Text] [Related]

  • 19. Thymidine as a kinetic and biochemical modulator of 1-beta-D-arabinofuranosylcytosine in human acute nonlymphocytic leukemia.
    Blumenreich MS, Chou TC, Andreeff M, Vale K, Clarkson BD, Young CW.
    Cancer Res; 1984 Feb 15; 44(2):825-30. PubMed ID: 6692380
    [Abstract] [Full Text] [Related]

  • 20. Effect of amsacrine on ara-CTP cellular pharmacology in human leukemia cells during high-dose cytarabine therapy.
    Plunkett W, Nowak B, Keating MJ.
    Cancer Treat Rep; 1987 May 15; 71(5):479-83. PubMed ID: 3567973
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.